Autologous peripheral blood stem cell transplantation for myocardial regeneration: A novel strategy for cell collection and surgical injection

Giulio Pompilio, Aldo Cannata, Fedro Peccatori, Francesco Bertolini, Angelo Nascimbene, Maurizio C. Capogrossi, Paolo Biglioli

Research output: Contribution to journalArticle

Abstract

Purpose Bone-marrow and peripheral blood-derived stem cells can be used as stimulators of myogenesis and angiogenesis. We describe an original technique for collection and surgical intramyocardial injection of peripheral blood-derived stem cells. Description Stem cells are mobilized from the bone marrow by means of subcutaneous administration of Lenogastrim (Granocyte 34 [Aventis Pharma, Milan, Italy]) for 4 days. Then the day before the operation the peripheral blood-derived stem cells are collected by means of apheresis and processed in order to obtain the CD 133+ cells. Cells are injected into the myocardium in a beating heart in order to induce angiogenesis locally or myogenesis, or both. When necessary, off-pump coronary artery bypass grafting is previously accomplished. Evaluation Thus far we have investigated 4 patients (3 patients who have received off-pump peripheral blood stem cell injection and coronary bypass grafting through median sternotomies, and 1 patient who underwent cell transplant alone through a minimally-invasive transdiaphragmatic approach). No complications were noted at a mean of 4 months after surgery. Conclusions This novel method of peripheral bone marrow stem cell collection and intramyocardial injection seems to be safe, feasible, and reproducible. However, there is need of further evidence to definitely assess safety issues and clinical results.

Original languageEnglish
Pages (from-to)1808-1812
Number of pages5
JournalAnnals of Thoracic Surgery
Volume78
Issue number5
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Peripheral Blood Stem Cell Transplantation
Regeneration
Injections
Muscle Development
Stem Cells
Bone Marrow
Off-Pump Coronary Artery Bypass
Blood Component Removal
Sternotomy
Angiogenesis Inducing Agents
Coronary Artery Bypass
Bone Marrow Cells
Italy
Myocardium
Transplants
Safety
Peripheral Blood Stem Cells

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Autologous peripheral blood stem cell transplantation for myocardial regeneration : A novel strategy for cell collection and surgical injection. / Pompilio, Giulio; Cannata, Aldo; Peccatori, Fedro; Bertolini, Francesco; Nascimbene, Angelo; Capogrossi, Maurizio C.; Biglioli, Paolo.

In: Annals of Thoracic Surgery, Vol. 78, No. 5, 11.2004, p. 1808-1812.

Research output: Contribution to journalArticle

@article{49569a099a1f44189c9e6def55b5852b,
title = "Autologous peripheral blood stem cell transplantation for myocardial regeneration: A novel strategy for cell collection and surgical injection",
abstract = "Purpose Bone-marrow and peripheral blood-derived stem cells can be used as stimulators of myogenesis and angiogenesis. We describe an original technique for collection and surgical intramyocardial injection of peripheral blood-derived stem cells. Description Stem cells are mobilized from the bone marrow by means of subcutaneous administration of Lenogastrim (Granocyte 34 [Aventis Pharma, Milan, Italy]) for 4 days. Then the day before the operation the peripheral blood-derived stem cells are collected by means of apheresis and processed in order to obtain the CD 133+ cells. Cells are injected into the myocardium in a beating heart in order to induce angiogenesis locally or myogenesis, or both. When necessary, off-pump coronary artery bypass grafting is previously accomplished. Evaluation Thus far we have investigated 4 patients (3 patients who have received off-pump peripheral blood stem cell injection and coronary bypass grafting through median sternotomies, and 1 patient who underwent cell transplant alone through a minimally-invasive transdiaphragmatic approach). No complications were noted at a mean of 4 months after surgery. Conclusions This novel method of peripheral bone marrow stem cell collection and intramyocardial injection seems to be safe, feasible, and reproducible. However, there is need of further evidence to definitely assess safety issues and clinical results.",
author = "Giulio Pompilio and Aldo Cannata and Fedro Peccatori and Francesco Bertolini and Angelo Nascimbene and Capogrossi, {Maurizio C.} and Paolo Biglioli",
year = "2004",
month = "11",
doi = "10.1016/j.athoracsur.2003.09.084",
language = "English",
volume = "78",
pages = "1808--1812",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "The Society of Thoracic Surgeons. Published by Elsevier Inc",
number = "5",

}

TY - JOUR

T1 - Autologous peripheral blood stem cell transplantation for myocardial regeneration

T2 - A novel strategy for cell collection and surgical injection

AU - Pompilio, Giulio

AU - Cannata, Aldo

AU - Peccatori, Fedro

AU - Bertolini, Francesco

AU - Nascimbene, Angelo

AU - Capogrossi, Maurizio C.

AU - Biglioli, Paolo

PY - 2004/11

Y1 - 2004/11

N2 - Purpose Bone-marrow and peripheral blood-derived stem cells can be used as stimulators of myogenesis and angiogenesis. We describe an original technique for collection and surgical intramyocardial injection of peripheral blood-derived stem cells. Description Stem cells are mobilized from the bone marrow by means of subcutaneous administration of Lenogastrim (Granocyte 34 [Aventis Pharma, Milan, Italy]) for 4 days. Then the day before the operation the peripheral blood-derived stem cells are collected by means of apheresis and processed in order to obtain the CD 133+ cells. Cells are injected into the myocardium in a beating heart in order to induce angiogenesis locally or myogenesis, or both. When necessary, off-pump coronary artery bypass grafting is previously accomplished. Evaluation Thus far we have investigated 4 patients (3 patients who have received off-pump peripheral blood stem cell injection and coronary bypass grafting through median sternotomies, and 1 patient who underwent cell transplant alone through a minimally-invasive transdiaphragmatic approach). No complications were noted at a mean of 4 months after surgery. Conclusions This novel method of peripheral bone marrow stem cell collection and intramyocardial injection seems to be safe, feasible, and reproducible. However, there is need of further evidence to definitely assess safety issues and clinical results.

AB - Purpose Bone-marrow and peripheral blood-derived stem cells can be used as stimulators of myogenesis and angiogenesis. We describe an original technique for collection and surgical intramyocardial injection of peripheral blood-derived stem cells. Description Stem cells are mobilized from the bone marrow by means of subcutaneous administration of Lenogastrim (Granocyte 34 [Aventis Pharma, Milan, Italy]) for 4 days. Then the day before the operation the peripheral blood-derived stem cells are collected by means of apheresis and processed in order to obtain the CD 133+ cells. Cells are injected into the myocardium in a beating heart in order to induce angiogenesis locally or myogenesis, or both. When necessary, off-pump coronary artery bypass grafting is previously accomplished. Evaluation Thus far we have investigated 4 patients (3 patients who have received off-pump peripheral blood stem cell injection and coronary bypass grafting through median sternotomies, and 1 patient who underwent cell transplant alone through a minimally-invasive transdiaphragmatic approach). No complications were noted at a mean of 4 months after surgery. Conclusions This novel method of peripheral bone marrow stem cell collection and intramyocardial injection seems to be safe, feasible, and reproducible. However, there is need of further evidence to definitely assess safety issues and clinical results.

UR - http://www.scopus.com/inward/record.url?scp=19644374623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19644374623&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2003.09.084

DO - 10.1016/j.athoracsur.2003.09.084

M3 - Article

C2 - 15511478

AN - SCOPUS:19644374623

VL - 78

SP - 1808

EP - 1812

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -